Monopar Therapeutics Inc MNPR

NAS: MNPR | ISIN: US61023L1089 1/05/2025

43,15 USD (+3,18%)

(+3,18%) 1/05/2025

Grafiek Monopar Therapeutics Inc

Grafiek Monopar Therapeutics Inc

1 dag1d 3,18%
1 week1w 1,03%
1 maand1m 11,99%
3 maanden3m -0,92%
6 maanden6m 154,42%
1 jaar1j 6.437,88%
5 jaar5j 483,11%

Monopar Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

2 november 2023 · Thinking about buying stock in AGNC Investment, Enphase Energy, Ford Motor, Energy Transfer, or Monopar Therapeutics? · Persbericht

5 oktober 2022 · Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis · Persbericht

13 september 2021 · Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe · Persbericht

24 mei 2021 · Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery · Persbericht

2 maart 2021 · Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery · Persbericht

24 februari 2021 · Monopar Therapeutics to Present at Upcoming Investor Conferences · Persbericht

Profiel Monopar Therapeutics Inc

Gezondheidstechnologie

Website: www.monopartx.com

Hoofdzetel: Wilmette, Illinois Verenigde Staten

Werknemers: 19

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe